PFE241206C22500
- 3.35
- 0.000.00%
Pfizer Newsroom
10 Health Care Stocks Whale Activity In Today's Session
Pfizer Is Maintained at Buy by Guggenheim
Pfizer Analyst Ratings
Express News | Reuters Next - Pfizer's Roan Says Unh Exec's Murder Was a "Tragedy of Epic Proportions"
Express News | Reuters Next - Pfizer's Roan Says We Need to Get Behind the Disease Prevention Message
Express News | Reuters Next - Pfizer's Roan Says Going to Work Hard to Ensure Ecosystem That Drives Vaccines & New Medicines Is Robust and Healthy
Market Climbs on CPI Inflation and Likelihood of Rate Cuts | Livestock
Express News | Reuters Next - Pfizer Chief Sustainability Officer Caroline Roan Says Need to Double Down on Climate Investments in Low Income Countries
Guggenheim Maintains Pfizer(PFE.US) With Buy Rating, Cuts Target Price to $33
Pfizer Price Target Lowered to $33 From $35 at Guggenheim
Evercore Maintains Pfizer(PFE.US) With Buy Rating
Pfizer (PFE) Gets a Buy From Evercore ISI
NCCN Announces Funding for a Prostate Cancer Research Project
Express News | Pfizer : Leerink Partners Cuts Target Price to $28 From $31
REGISTRATION OPEN FOR THE 13th ANNUAL BUSINESS ARCHITECTURE INNOVATION SUMMIT
Guggenheim Adjusts Price Target on Pfizer to $33 From $35, Keeps Buy Rating
Is Pfizer Inc. (PFE) the Best American Dividend Stock to Buy Right Now?
The clinical results of the protein degradation combination therapy by Arvinas and Pfizer (PFE.US) are positive, with a clinical benefit rate for patients exceeding 62%.
Arvinas and Pfizer (PFE.US) today announced preliminary data from the ongoing Phase 1b clinical trial TACTIVE-U sub-study.
BofA Restarts Coverage of 11 Large-cap Biopharmas
Pfizer Options Spot-On: On December 10th, 241.35K Contracts Were Traded, With 3.46 Million Open Interest